Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • DeCarvalho
    Junior Member
    • Jun 2012
    • 1

    #1

    Postdoctoral Fellow in Cancer Epigenomics at Ontario Cancer Institute - Toronto

    The Ontario Cancer Institute (OCI) at Princess Margaret Hospital - a teaching hospital of the University of Toronto - ranks in the top 5 cancer research centers in the world. Its research activities are concentrated on epigenomics, cancer immunotherapy, cancer stem cells, image-guided therapeutics, patient survivorship, and personalized medicine. The University of Toronto and its affiliated hospital research institutes comprise one of the largest and most productive centers of biomedical research in North America while the City of Toronto is ranked fourth in the Economist’s list of World’s Most Liveable Cities, and second in PriceWaterhouseCooper’s Cities of Opportunity in 2011.
    For more information about the institute: http://www.uhntrainees.ca/

    Computational Biology

    A bioinformatics Postdoctoral Fellow or Research Associate position is available immediately within the group of Daniel D. De Carvalho, Ph.D. Our lab focuses on understanding the mechanisms driving cancer-specific epigenetic alterations, with the ultimate goal of allowing target-specific epigenetic interventions. To achieve this goal, we perform functional genomic screening, combined with systems biology and a variety of genome-wide profiling of epigenetic modifications, using next-generation sequencing (NGS) and microarray technologies. We are specifically seeking individuals with strong computational, bioinformatics, and/or statistical backgrounds to be involved in NGS data analysis. Applicants must be highly motivated and able to communicate effectively in English.

    For more information about our work, prospective applicants are encouraged to refer to the following papers:
    Cancer Cell. 2012 May 25;21(5):655-67 (PMID: 22624715);
    Cell. 2011 Dec 9;147(6):1283-94 (PMID: 22153073);
    PNAS. 2011 Aug 30;108(35):14497-502 (PMID: 21844352);
    PLoS Genet. 2011 Feb 3;7(2):e1001286 (PMID: 21304883);
    Nat Biotechnol. 2010 Oct 13;28(10):1069- 1078 (PMID: 20944599);
    Oncogene. 2011 Jan 13;30(2):223-33 (PMID: 20838376).

    Please send your curriculum vitae and the contact information for 3 references to Daniel D. De Carvalho, Ph.D. ([email protected]).

Latest Articles

Collapse

  • SEQadmin2
    Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
    by SEQadmin2



    CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

    Despite this, “CRISPR helped turn genome editing from a specialized technique into
    ...
    07-31-2026, 11:01 AM
  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM
  • SEQadmin2
    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
    by SEQadmin2



    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
    ...
    07-09-2026, 11:10 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 08-03-2026, 10:13 AM
0 responses
15 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-31-2026, 02:55 AM
0 responses
32 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-24-2026, 12:17 PM
0 responses
23 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-23-2026, 11:41 AM
0 responses
21 views
0 reactions
Last Post SEQadmin2  
Working...